Annovis Bio director buys 713,800 shares at $2.10

Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock.

(High)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Annovis Bio director Michael B. Hoffman made a large open-market purchase of the company’s common stock. On April 2, 2026, he bought 713,800 shares at $2.10 per share, increasing his direct holdings to 3,288,539 shares.

He also has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust, over which he has both voting and investment power. The filing shows no derivative securities remaining, so this activity reflects a direct cash investment rather than an options exercise.

Insider Trade Summary

Net Buyer: 713,800 shares

Net Buy 2 txns

Insider Hoffman Michael B

Role Director

Bought 713,800 shs ($1.50M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	713,800	$2.10	$1.50M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,288,539 shares (Direct); Common Stock — 223,357 shares (Indirect, The 2024 Hoffman Family Trust)

Footnotes (1)

F1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

Key Figures

Shares purchased: 713,800 shares Purchase price: $2.10 per share Direct holdings after: 3,288,539 shares +2 more

5 metrics

Shares purchased 713,800 shares Open-market purchase of common stock on April 2, 2026

Purchase price $2.10 per share Price paid for Annovis Bio common stock

Direct holdings after 3,288,539 shares Common stock directly owned following transaction

Indirect trust holdings 223,357 shares Held by The 2024 Hoffman Family Trust with Hoffman’s voting and investment power

Net buy shares 713,800 shares Net buy direction per transaction summary

Key Terms

open-market purchase, indirect ownership, voting and investment power, family trust

4 terms

open-market purchase financial

"The filing classifies the transaction as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"he has indirect ownership of 223,357 shares held by The 2024 Hoffman Family Trust"

voting and investment power financial

"the reporting person has voting and investment power over such shares"

family trust financial

"The shares are held in a family trust formed by the reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Annovis Bio (ANVS) report for Michael B. Hoffman?

Annovis Bio reported that director Michael B. Hoffman made an open-market purchase of 713,800 shares of common stock at $2.10 per share. This transaction occurred on April 2, 2026 and increased his overall ownership stake in the company.

How many Annovis Bio (ANVS) shares does Michael B. Hoffman own after this trade?

After the trade, Michael B. Hoffman directly owns 3,288,539 Annovis Bio common shares. In addition, he has indirect ownership of 223,357 shares through The 2024 Hoffman Family Trust, where he holds both voting and investment power over those shares.

Was the Annovis Bio (ANVS) insider trade an open-market purchase?

Yes. The filing classifies the transaction as an open-market purchase of common stock at $2.10 per share. This means Hoffman used cash to buy shares on the market rather than receiving them through options, grants, or other derivative-based compensation.

Does Michael B. Hoffman hold Annovis Bio (ANVS) shares through a family trust?

Yes. The filing states that 223,357 Annovis Bio common shares are held by The 2024 Hoffman Family Trust. Hoffman formed this trust and retains both voting and investment power over those indirectly held shares, in addition to his direct holdings.

Did the Annovis Bio (ANVS) Form 4 include any option exercises or derivatives?

No. The summarized data show no derivative transactions or remaining derivative positions for Michael B. Hoffman. The reported activity is exclusively in common stock, reflecting a straightforward share purchase rather than an option exercise or other derivative event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/03/2026 - 05:06 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last)

(First)

(Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN

PENNSYLVANIA

19355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/02/2026		P		713,800	A	$2.1	3,288,539	D
Common Stock								223,357	I	The 2024 Hoffman Family Trust⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

	/s/ Maria Maccecchini Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR